"bharat-biotech"

Says final decision with government, all norms followed in vaccine approval

The Drugs Controller General of India (DCGI) on Sunday approved Oxford COVID-19 vaccine Covishield

The Drugs Controller General of India on Sunday gave the permission to Bharat Biotech's Covaxin for use in an emergency situation.

The approval to Covaxin has been questioned by industry experts and some opposition Congress leaders who have expressed concern over the absence of phase 3 trial data

The Brazilian Association of Vaccine Clinics (ABCVAC) confirmed on its website it had signed a memorandum of understanding with the Indian firm to purchase its Covaxin vaccine

It was not just the invisible pathogen that engaged scientists in 2020 but also the vast expanse of the cosmos

"Following the emergency use permission, the company is in a position to meet any production requirement that the government may have at this time,” company officials said

While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. Covaxin has generated excellent safety data with robust immune responses

Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV).

This is a major relief for India which has the second highest number of infections in the world, after the US. The Central government plans to vaccinate nearly 30 crore people in the first phase of drive in the next six to eight months.

The application will be sent to Drugs Controller General of India (DCGI) V.G. Somani for final approval

The discussion revolved around the status of the indigenous vaccine and the plans to make it available in India and rest of the world

Companies to co-develop Covaxin to prevent Covid-19 infection in the US

Trials that began during mid-November are targeted to be done in 26,000 volunteers across multiple sites in India

It also said that protective level of antibodies generally develop two weeks after receiving the second dose.

Strong regional parties are more conducive for the consolidation and progress of the new States

The project update on Covaxin was presented to the delegates by Dr Krishna Ella, chairman and managing director, Bharat Biotech.

The visit by the heads of foreign missions was organised by the Ministry of External Affairs (MEA) and was part of India's efforts to develop partnerships for the manufacture and delivery of vaccines

The Ministry of External Affairs has made elaborate arrangements for the visit of the diplomats to the two manufacturing units at Medchal and Shamirpet.

In a session titled ‘Transformation of India with a focus on the entrepreneur ecosystem’ Kant said that India has grown as a technology country.